TY - JOUR
T1 - Regeneration of CD8αβ T cells from T-cell-derived iPSC imparts potent tumor antigen-specific cytotoxicity
AU - Maeda, Takuya
AU - Nagano, Seiji
AU - Ichise, Hiroshi
AU - Kataoka, Keisuke
AU - Yamada, Daisuke
AU - Ogawa, Seishi
AU - Koseki, Haruhiko
AU - Kitawaki, Toshio
AU - Kadowaki, Norimitsu
AU - Takaori-Kondo, Akifumi
AU - Masuda, Kyoko
AU - Kawamoto, Hiroshi
N1 - Funding Information:
We thank Eri Satoh and Toshika Senba for technical support; Mahito Nakanishi and Manami Ohtaka for kindly providing Sendai virus of Yamanaka factors; Haruo Sugiyama and Fumihiro Fujiki (Osaka University), Masahiro Kawahara (Shiga University of Medical Science), and Yutaka Shimazu and Masaki Miyazaki (Kyoto University) for helpful discussion; and Peter Burrows (University of Alabama) for critical reading of the manuscript. This work was supported by a Project for the Development of Innovative Research on Cancer Therapeutics (P-Direct) from the Ministry of Education, Culture, Sports, Science and Technology, Japan, by Astlym Co. Ltd, and by RegCell, Inc. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Publisher Copyright:
©2016 AACR.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Although adoptive transfer of cytotoxic T lymphocytes (CTL) offer a promising cancer therapeutic direction, the generation of antigen-specific CTL from patients has faced difficulty in efficient expansion in ex vivo culture. To resolve this issue, several groups have proposed that induced pluripotent stem cell technology be applied for the expansion of antigen-specific CTL, which retain expression of the same T-cell receptor as original CTL. However, in these previous studies, the regenerated CTL are mostly of the CD8αα+ innate type and have less antigen-specific cytotoxic activity than primary CTL. Here we report that, by stimulating purified iPSC-derived CD4/CD8 double-positive cells with anti-CD3 antibody, T cells expressing CD8αβ were generated and exhibited improved antigen-specific cytotoxicity compared with CD8αα+ CTL. Failure of CD8αβ T-cell production using the previous method was found to be due to killing of double-positive cells by the double-negative cells in the mixed cultures. We found that WT1 tumor antigen-specific CTL regenerated by this method prolonged the survival of mice bearing WT1-expressing leukemic cells. Implementation of our methods may offer a useful clinical tool.
AB - Although adoptive transfer of cytotoxic T lymphocytes (CTL) offer a promising cancer therapeutic direction, the generation of antigen-specific CTL from patients has faced difficulty in efficient expansion in ex vivo culture. To resolve this issue, several groups have proposed that induced pluripotent stem cell technology be applied for the expansion of antigen-specific CTL, which retain expression of the same T-cell receptor as original CTL. However, in these previous studies, the regenerated CTL are mostly of the CD8αα+ innate type and have less antigen-specific cytotoxic activity than primary CTL. Here we report that, by stimulating purified iPSC-derived CD4/CD8 double-positive cells with anti-CD3 antibody, T cells expressing CD8αβ were generated and exhibited improved antigen-specific cytotoxicity compared with CD8αα+ CTL. Failure of CD8αβ T-cell production using the previous method was found to be due to killing of double-positive cells by the double-negative cells in the mixed cultures. We found that WT1 tumor antigen-specific CTL regenerated by this method prolonged the survival of mice bearing WT1-expressing leukemic cells. Implementation of our methods may offer a useful clinical tool.
UR - http://www.scopus.com/inward/record.url?scp=85002980375&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85002980375&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-16-1149
DO - 10.1158/0008-5472.CAN-16-1149
M3 - Article
C2 - 27872100
AN - SCOPUS:85002980375
SN - 0008-5472
VL - 76
SP - 6839
EP - 6850
JO - Cancer Research
JF - Cancer Research
IS - 23
ER -